Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.23 | — | — | — | — | — | — | — | — | — | 2.36 | — | — | — | — | — | 1.62 | — | — | 4.06 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.03 | 3.49 | 4.35 | 4.01 | 8.91 | 2.26 | 2.62 | 1.45 | 2.32 | 3.03 | 4.20 | 4.29 | 5.28 | 6.36 | 5.29 | 1.97 | 0.74 | 3.67 | 21.29 | 2.52 | 12.52 |
| — | +54.7% | +66.0% | +176.5% | +284.6% | -25.5% | -37.5% | -66.2% | -56.1% | -52.4% | -20.6% | +117.7% | +609.2% | +73.2% | -75.2% | -21.6% | -94.1% | — | — | — | — | |
| P/B Ratio | 4.42 | 6.12 | 7.00 | 7.20 | 6.96 | 2.34 | 2.95 | 1.69 | 1.95 | 2.77 | 2.90 | 5.23 | 5.10 | 5.37 | 3.46 | 4.00 | 2.83 | 11.24 | 12.54 | 16.42 | 15.79 |
| — | +161.4% | +137.8% | +325.2% | +256.7% | -15.6% | +1.4% | -67.6% | -61.7% | -48.3% | -16.0% | +30.8% | +80.5% | -52.2% | -72.4% | -75.6% | -82.1% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | 63.26 | — | — | — | — | — | — | — | — | — | — | — | 40.73 | 22.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | 2.22 | — | — | — | — | — | 0.94 | — | — | 3.56 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 2.22 | — | — | — | — | — | 1.18 | — | — | 3.58 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.7% | 4.6% | 15.3% | 24.4% | 18.7% | 50.1% | 53.2% | 48.6% | 44.0% | 38.3% | 32.3% | 37.8% | 44.9% | 17.1% | 38.9% | -9.3% | 80.1% | -120.8% | 36.6% | 89.8% | 17.1% |
| — | -90.9% | -71.3% | -49.8% | -57.4% | +30.7% | +64.5% | +28.5% | -2.1% | +124.3% | -16.8% | +508.2% | -43.9% | +114.1% | +6.3% | -110.3% | +367.6% | -427.5% | -41.8% | +421.1% | -40.2% | |
| Operating Margin | -46.7% | -77.8% | -76.7% | -58.1% | -126.2% | -22.5% | -12.1% | -39.4% | -27.2% | -56.6% | 208.2% | -59.4% | -58.3% | -45.7% | -49.5% | -50.6% | 59.6% | -184.9% | -84.3% | 63.3% | -226.6% |
| — | -246.1% | -533.4% | -47.2% | -364.5% | +60.3% | -105.8% | +33.6% | +53.4% | -23.8% | +521.0% | -17.5% | -198.0% | +75.3% | +41.3% | -179.9% | +126.3% | -37.9% | -1552.1% | +122.7% | -30.6% | |
| Net Margin | -66.0% | -89.3% | -103.8% | -104.9% | -150.8% | -24.0% | -18.8% | -69.9% | -20.2% | -65.5% | 179.9% | -76.8% | -89.9% | -42.1% | -54.1% | -39.7% | 46.2% | -203.8% | -119.2% | 62.0% | -241.7% |
| — | -272.6% | -453.5% | -50.1% | -648.3% | +63.4% | -110.4% | +9.0% | +77.6% | -55.8% | +432.5% | -93.4% | -294.5% | +79.4% | +54.6% | -164.0% | +119.1% | -70.8% | -2879.6% | +118.5% | -25.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -80.2% | -40.2% | -35.1% | -39.0% | -26.3% | -6.4% | -5.2% | -18.6% | -4.8% | -14.0% | 36.1% | -21.8% | -19.7% | -8.6% | -8.5% | -23.0% | 56.1% | -120.4% | -16.3% | 139.3% | -90.7% |
| — | -527.2% | -577.0% | -110.1% | -447.0% | +54.3% | -114.4% | +14.9% | +75.5% | -63.9% | +522.2% | +5.1% | -135.0% | +92.9% | +47.7% | -116.5% | +161.8% | -182.0% | -511.2% | +456.5% | -353.7% | |
| ROA | -25.6% | -8.3% | -8.3% | -11.8% | -9.6% | -2.4% | -1.9% | -7.3% | -1.9% | -5.1% | 12.1% | -6.5% | -6.4% | -3.0% | -3.0% | -6.7% | 10.2% | -19.4% | -3.3% | 22.1% | -8.9% |
| — | -243.7% | -342.5% | -62.3% | -412.7% | +52.8% | -115.5% | -12.0% | +70.8% | -72.2% | +504.9% | +3.0% | -163.3% | +84.6% | +8.3% | -130.3% | +214.4% | -257.5% | -613.1% | +352.6% | -21.4% | |
| ROIC | -28.3% | -11.8% | -9.2% | -10.2% | -13.1% | -3.6% | -1.9% | -6.4% | -3.7% | -6.9% | 23.0% | -9.3% | -10.5% | -11.6% | -13.4% | -57.0% | 106.8% | — | — | — | — |
| — | -230.1% | -378.0% | -60.3% | -255.7% | +48.1% | -108.4% | +31.6% | +65.0% | +40.4% | +272.0% | +83.7% | -109.9% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.95 | 2.59 | 2.73 | 1.95 | 1.30 | 1.06 | 1.20 | 1.19 | 0.93 | 1.26 | 1.12 | 1.52 | 1.23 | 0.78 | 0.75 | 0.69 | 0.98 | 1.43 | 0.78 | 0.67 | 1.45 |
| — | +145.3% | +126.7% | +63.6% | +40.6% | -16.2% | +7.7% | -21.4% | -25.1% | +61.1% | +50.0% | +118.9% | +26.0% | -45.3% | -4.2% | +3.1% | -32.3% | -29.3% | -42.8% | -53.7% | +42.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 3.21 | — | — | — | — | — | 1.65 | — | — | 0.64 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.38 | 2.16 | 2.14 | 2.38 | 1.78 | 2.27 | 2.70 | 2.61 | 2.78 | 2.63 | 2.64 | 1.65 | 1.47 | 1.42 | 1.48 | 1.53 | 1.27 | 1.16 | 1.50 | 1.59 | 1.23 |
| — | -4.8% | -20.9% | -8.6% | -35.9% | -13.7% | +2.5% | +57.7% | +89.2% | +85.4% | +78.4% | +8.1% | +15.4% | +22.6% | -1.4% | -3.6% | +3.5% | -11.3% | -14.4% | +3.0% | -49.2% | |
| Quick Ratio | 1.85 | 1.69 | 1.60 | 1.85 | 1.36 | 1.77 | 2.12 | 2.14 | 2.25 | 2.15 | 2.22 | 1.37 | 1.30 | 1.28 | 1.33 | 1.40 | 1.02 | 0.94 | 1.12 | 1.25 | 0.95 |
| — | -4.7% | -24.6% | -13.8% | -39.8% | -17.4% | -4.4% | +55.8% | +73.8% | +68.1% | +66.8% | -2.1% | +27.6% | +36.5% | +19.3% | +12.2% | +6.4% | -6.1% | -30.3% | -10.7% | -55.1% | |
| Interest Coverage | -1.72 | -5.23 | -4.65 | -1.07 | -6.58 | -1.11 | -1.00 | -4.16 | -1.26 | -4.08 | 9.36 | -1.60 | -7.77 | -4.44 | -2.58 | -7.46 | 14.92 | -40.97 | -3.90 | 37.12 | -4.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VALN stock.
Valneva SE's current P/E is -4.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Valneva SE's current operating margin is -46.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Valneva SE's business trajectory between earnings reports.